文献速递前列腺癌

寡复发前列腺癌患者队列研究:前列腺特异性膜抗原放射引导下挽救性淋巴结清扫的肿瘤学结局

Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
PubMed 文献 · Eur Urol · 2022-06-17

本队列研究评估了364例根治性前列腺切除术后生化复发、经PSMA PET显像后接受PSMA放射引导下挽救性手术的寡复发前列腺癌患者的肿瘤学结局。2年无生化复发生存率为32%,无治疗生存率为58%;术前PSA较高、PSMA阳性病灶数较多、多部位(盆腔加腹膜后)病灶及腹膜后病灶是术后生化复发的独立预测因素。主要局限性为缺乏对照组。

要点

  • 2年无生化复发生存率为32%,无治疗生存率为58%。
  • 术前PSA较高、PSMA阳性病灶数较多、多部位及腹膜后病灶是生化复发的独立预测因素。
  • 6.6%的患者在3个月内发生Clavien-Dindo III-IV级并发症。

核心结论

  • 在寡复发前列腺癌中,挽救性手术目前仍属实验性治疗,须根据预期寿命、低PSA值和盆腔内少量PSMA PET阳性病灶仔细选择患者。

研究设计与样本

  • 队列研究,纳入2014年至2020年在两家三级医疗中心接受PSMA放射引导下挽救性手术的根治性前列腺切除术后生化复发且PSMA PET显像的寡复发前列腺癌患者,共评估364例未接受伴随治疗的患者。

主要发现

  • 在PSMA放射引导下挽救性手术中,343例(94%)患者切除了转移性软组织前列腺癌病灶。
  • 术后2-16周,165例患者达到前列腺特异性抗原(PSA)<0.2 ng/ml。
  • 3个月内,24例(6.6%)患者发生Clavien-Dindo III-IV级并发症。
  • 2年无生化复发生存率为32%,无治疗生存率为58%。
  • 多变量分析中,术前PSA较高(风险比[HR]:1.07,95%置信区间[CI]:1.02-1.12)、PSMA阳性病灶数较多(HR:1.23,CI:1.08-1.40)、多部位(盆腔加腹膜后)病灶(HR:1.90,CI:1.23-2.95)及术前影像病灶位于腹膜后(HR:2.04,CI:1.31-3.18)是PSMA放射引导下挽救性手术后生化复发的独立预测因素。

临床怎么用

  • 作者认为,寡复发前列腺癌的挽救性手术目前是实验性治疗,必须根据预期寿命、低PSA值和盆腔内少量PSMA PET阳性病灶仔细选择患者。

局限性

  • 主要局限性是缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a subset of patients with recurrent oligometastatic prostate cancer (PCa) salvage surgery with prostate-specific membrane antigen (PSMA)-targeted radioguidance (PSMA-RGS) might be of value. OBJECTIVE: To evaluate the oncological outcomes of salvage PSMA-RGS and determine the predictive preoperative factors of improved outcomes. DESIGN, SETTING, AND PARTICIPANTS: A cohort study of oligorecurrent PCa patients with biochemical recurrence (BCR) after radical prostatectomy and imaging with PSMA positron emission tomography (PET), treated with PSMA-RGS in two tertiary care centers (2014-2020), was conducted. INTERVENTION: PSMA-RGS. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier and multivariable Cox regression models were used to assess BCR-free (BFS) and therapy-free (TFS) survival. Postoperative complications were classified according to Clavien-Dindo. RESULTS AND LIMITATIONS: Overall, 364 patients without concomitant treatment were assessed. At PSMA-RGS, metastatic soft-tissue PCa lesions were removed in 343 (94%) patients. At 2-16 wk after PSMA-RGS, 165 patients reached a prostate-specific antigen (PSA) level of <0.2 ng/ml. Within 3 mo, 24 (6.6%) patients suffered from Clavien-Dindo complications grade III-IV. At 2 yr, BFS and TFS rates were 32% and 58%, respectively. In multivariable analyses, higher preoperative PSA (hazard ratio [HR]: 1.07, 95% confidence interval [CI]: 1.02-1.12), higher number of PSMA-avid lesions (HR: 1.23, CI: 1.08-1.40), multiple (pelvic plus retroperitoneal) localizations (HR: 1.90, CI: 1.23-2.95), and retroperitoneal localization (HR: 2.04, CI: 1.31-3.18) of lesions in preoperative imaging were independent predictors of BCR after PSMA-RGS. The main limitation is the lack of a control group. CONCLUSIONS: As salvage surgery in oligorecurrent PCa currently constitutes an experimental treatment approach, careful patient selection is mandatory based on life expectancy, low PSA values, and low number of PSMA PET-avid lesions located in the pelvis. PATIENT SUMMARY: We looked at the outcomes from prostate cancer patients with recurrent disease after radical prostatectomy. We found that surgery may be an opportunity to prolong treatment-free survival, but patient selection criteria need to be very narrow.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Knipper S, Mehdi Irai M, Simon R, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol. 2022. PMID: 35718637. doi:10.1016/j.eururo.2022.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。